{"id":52711,"date":"2023-11-13T13:41:49","date_gmt":"2023-11-13T12:41:49","guid":{"rendered":"https:\/\/haei.org\/?p=52711"},"modified":"2023-11-16T13:43:26","modified_gmt":"2023-11-16T12:43:26","slug":"orchard-reports-q3-2023-financial-results-and-highlights-recent-business-accomplishments","status":"publish","type":"post","link":"https:\/\/haei.org\/orchard-reports-q3-2023-financial-results-and-highlights-recent-business-accomplishments\/","title":{"rendered":"Orchard reports Q3 2023 financial results and highlights recent business accomplishments"},"content":{"rendered":"
Orchard Therapeutics reports third quarter 2023 financial results and highlights recent business accomplishments <\/strong><\/p>\n Orchard Therapeutics announced several business accomplishments along with its financial results for the quarter ended 30 September 2023.<\/p>\n Bobby Gaspar MD PhD, Chief Executive Officer of Orchard Therapeutics, said: \u201cWith strong execution across our key commercial, regulatory and clinical priorities, 2023 has been a transformational year for Orchard Therapeutics, culminating with the announcement of the planned acquisition by Kyowa Kirin.\u201d<\/p>\n Selected HAE 2023 Expected Milestones<\/strong><\/p>\n Orchard Therapeutics has outlined that for the remainder of 2023 it expects to advance the company\u2019s other pre-clinical programs, which includes OTL-204 in the progranulin form of FTD and OTL-105 partnered with and funded by Pharming Group N.V. in hereditary angioedema (HAE).<\/p>\n (Source: Orchard)<\/p>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":52712,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"yoast_head":"\n